Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00818441 · ClinicalTrials.gov registry record · Phase 2
Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 119
- Enrollment target
NCT00818441 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 119 participants.
The verdict
NCT00818441, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 119 participants
- Enrollment target
Study Summary
This study will explore the safety and efficacy of the oral PanHER inhibitor PF-00299804 in patients with adenocarcinoma of the lung who are either non-smokers (\<100 cigarette, cigar or pipe lifetime) or former light smokers ( less than 10 pack-years and stopped at least 15 years) or have known EGFR activating mutation; or patients with HER 2 amplification or mutation.
Interventions
- DRUG Dacomitinib (PF-00299804)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2009-03-11 |
| Est. Completion | 2015-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00818441
The ClinicalTrials.gov registry entry for NCT00818441 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dacomitinib (PF-00299804) is the first listed.
NCT00818441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00818441 about?
NCT00818441 is a clinical study titled "Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung". This study will explore the safety and efficacy of the oral PanHER inhibitor PF-00299804 in patients with adenocarcinoma of the lung who are either non-smokers (\<100 cigarette, cigar or pipe lifetime) or former light smokers ( less than 10 pack-years and stopped at least 15 years) or have known EGF...
What is the current status of trial NCT00818441?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2009-03-11. Estimated completion is 2015-04-30.
What interventions are being tested in trial NCT00818441?
The interventions under investigation include: Dacomitinib (PF-00299804) (DRUG).
Who is sponsoring clinical trial NCT00818441?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.